Grifols Egypt for Plasma Derivatives (GEPD) is a joint‑venture between the Egyptian Government’s National Service Projects Organization and the global plasma medicines leader Grifols. The company is building 20 plasma donation centers across Egypt and a state‑of‑the‑art manufacturing complex that can process up to 1 million liters of plasma per year, with the capacity to double in the future. As the first Egyptian source member of the Plasma Protein Therapeutics Association, GEPD is pioneering a public‑private alliance that will drive regional self‑sufficiency in critical plasma‑derived therapies. Its integrated approach—combining collection, fractionation, purification, and fill‑and‑finish operations—positions GEPD as a key player in improving access to high‑quality plasma medicines for the Egyptian healthcare system.
To ensure accurate and efficient inventory management by monitoring stock levels, maintaining inventory records, and supporting inventory-related processes.
Grifols Egypt for Plasma Derivatives (GEPD) is a joint‑venture between the Egyptian Government’s National Service Projects Organization and the global plasma medicines leader Grifols. The company is building 20 plasma donation centers across Egypt and a state‑of‑the‑art manufacturing complex that can process up to 1 million liters of plasma per year, with the capacity to double in the future. As the first Egyptian source member of the Plasma Protein Therapeutics Association, GEPD is pioneering a public‑private alliance that will drive regional self‑sufficiency in critical plasma‑derived therapies. Its integrated approach—combining collection, fractionation, purification, and fill‑and‑finish operations—positions GEPD as a key player in improving access to high‑quality plasma medicines for the Egyptian healthcare system.
Grifols Egypt for Plasma Derivatives